Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Endocrinology
•
Preventive Cardiology
•
Lipid Disorders
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
TACTiC trial
Related Questions
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
In ischemic stroke patients with low LDL levels (<30-50 mg/dl), would you consider lowering LDL levels to lower values without concern for any side effects?
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
Is there a role of prophylactic aspirin in patients with incidental findings of aortic atherosclerosis but no history CAD or CVA?
Should CT coronary calcium score be avoided in dialysis patients in light of presumed high prevalence of CAC in this population?
